ArticleRheumatology and therapy2026

Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study.

Andrew Östör et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.